Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118040 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00118040: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00118040 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118040, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors learn how genistein or placebo works in patients with bladder cancer. This randomized phase II trial is studying genistein or placebo to compare how they work in patients who are undergoing surgery for bladder cancer.
Interventions
- DRUG Genistein
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- OTHER Placebo Administration
- PROCEDURE Therapeutic Conventional Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-06-24 |
| Est. Completion | 2010-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118040
The ClinicalTrials.gov registry entry for NCT00118040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Genistein is the first listed.
NCT00118040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118040 about?
NCT00118040 is a clinical study titled "Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer". Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors learn how genistein or placebo works in patients with bladder cancer. This rand...
What is the current status of trial NCT00118040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2005-06-24. Estimated completion is 2010-08-15.
What interventions are being tested in trial NCT00118040?
The interventions under investigation include: Genistein (DRUG), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Placebo Administration (OTHER), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00118040?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.